Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bain Capital and KKR are among three groups preparing bids for Sapporo Holdings' real estate business, valued at approximately $2.7 billion. Sapporo is selling its real estate hol ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital Ventures, the company first shared with Axios. Why it matters: Cyber ...